Skip to main content
Premium Trial:

Request an Annual Quote

FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel

NEW YORK (GenomeWeb) – AutoGenomics said today that its Infiniti Neural Response Panel — a genomic test that gauges risk for opioid dependency — has been granted designation as a breakthrough device by the US Food and Drug Administration.

Intended for use by physicians as an aid in prescribing pain medication, the Infiniti panel uses an algorithm to detect and weigh 16 genetic mutations involved in brain reward pathways, which in turn affect risk of opioid use disorder.

Under the FDA's breakthrough device program — which addresses medical tests or other devices that demonstrate potential to address unmet medical needs — the agency will provide its support to accelerate the advancement of AutoGenomics' test through the regulatory review process.

The company describes the Infiniti test, which it hopes to bring to market through the FDA's de novo premarket pathway, as borne of extensive review of the scientific literature. Investigators first gave a presentation on the approach at the American Association for Clinical Chemistry's annual meeting in San Diego last year.

"We believe that this multi-variant addiction panel with its predictive algorithm represents a significant tool for healthcare practitioners to identify and better manage patients at risk of opioid dependency," AutoGenomics President and CEO Fareed Kureshy said in a statement.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.